Stephen J. Hoffman, M.D., Ph.D.
Stephen Hoffman, M.D., Ph.D., joined the Dicerna board of directors in November 2007. Most recently, he served as the Chief Executive Officer of Aerpio Pharmaceuticals, Inc. from 2017 to 2019. Dr. Hoffman has been a senior advisor to PDL BioPharma, Inc. since February 2014. Prior to that, he served as a Managing Director at Skyline Ventures, a venture capital firm, from May 2007 until February 2014.
From January 2003 to March 2007, Dr. Hoffman was a general partner at TVM Capital, a venture capital firm. From 1994 to 2002, he served as President, Chief Executive Officer and a member of the board of directors of Allos Therapeutics, Inc., a biopharmaceutical company, where he remained as Chairman of the Board until it was acquired by Spectrum Pharmaceuticals, Inc. in September 2012. From 1990 to 1994, Dr. Hoffman completed a fellowship in clinical oncology and a residency/fellowship in dermatology, both at the University of Colorado. Dr. Hoffman was the scientific founder of Somatogen Inc., a biotechnology company that, in 1998, was acquired by Baxter International, Inc., where he held the position of vice president of science and technology from 1987 until 1990.
Dr. Hoffman currently serves on the boards of directors of AcelRx Pharmaceuticals, Inc., Apic Bio Inc. and Palleon Pharmaceuticals, Inc. Previously, he also served on the boards of directors of Genocea Biosciences, Inc. and Sirtris Pharmaceuticals, Inc., a pharmaceutical company that was acquired by GlaxoSmithKline in 2008.
Dr. Hoffman holds a Ph.D. in bio-organic chemistry from Northwestern University and an M.D. from the University of Colorado School of Medicine.